The purpose of this study is to assess whether plasma cell free DNA is an accurate tool that can early and dynamically inform on treatment outcome and an accessible source of tumor DNA to track tumor clonal evolution.
Study Type
OBSERVATIONAL
Enrollment
320
peripheral blood collection at treatment start, interm PET/CT, end of treatment PET/CT, one-year and two-year follow-up and or progression or relapse
Ruijin hospital
Shanghai, Shanghai Municipality, China
RECRUITINGprogression free survival
Time frame: 2-year
overall survival
Time frame: 2-year
Complete Response rate
Time frame: 6 weeks after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.